



Biologic RNA for Novel Therapeutics

Overview

AimRNA's novel RNA bioengineering platform technology produces a wide variety of biologic RNA molecules at high yield and on large scale through a cost-effective bacterial fermentation process.

Unique Approach

RNA based therapy is a validated approach with several drugs approved by the FDA. However, all RNA drugs on the market and under development are currently made in vitro by chemical synthesis.

Biologic RNAs are produced, folded, and tolerated within living cells, showing favorable cellular stability and higher activity than synthetic RNA agents – while having greatly reduced cost of goods. Furthermore, AimRNA's platform technology overcomes inherent production challenges, enabling mass production of high-quality RNA molecules.

Opportunity

AimRNA's biologic RNA can be utilized for development of RNA-targeted drugs and vaccines, and has resulted in strong proof-of-concept data for lethal lung and liver cancer.

RNA based therapy is a validated approach with the approval of eight drugs by the FDA in recent years. Currently, eight RNA Sars-CoV-2 vaccine candidates are being tested.

AimRNA's platform is ideal for developing the next generation of RNA therapeutics:

- Expands the range of druggable targets
- Enables in-house development of biologic RNA therapeutics

Intellectual Property

AimRNA has strong IP protection for the RNA production process and biologic RNA drug candidates.

Financing Plans

Currently raising \$500,000 to fund early IND-enabling studies and gather pre-clinical data.

At A Glance

Founded in 2017 - Sacramento, CA
Initial focus on lung and liver cancer, with proven efficacy and safety in animal models.

yu@aimrna.com

Developmental Funding

\$200k SBIR Phase I

Biologic RNA Highlights

- Produced, folded, and tolerated within living cells.
- Natural and highly structured
- Greatly reduced cost of goods

Milestones

- Selectivity to control target
- Efficacy and safety proven in animal models
- Exploring production at the GMP facility at UC Davis
- Gathering GLP pharm/tox data

TEAM

Aiming Yu - Founder, President

Dr. Yu has over 20 years of experience in drug development, DM/PK/PD, and pharmacology and experimental therapeutics. He is currently a Full Professor in the department of Biochemistry and Molecular Medicine at UC Davis School of Medicine where he studies noncoding RNA pharmacoeugenetics, and anticancer pharmacology and therapy.

Neelu Batra, Ph.D. – Scientist

Dr. Batra has over 6 years' experience in cancer therapy and RNA bioengineering technology.